Analyst Reco. Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
40.1 ^USD	+1.52%		-0.52%	-12.94%

Mar. 11	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM
Mar. 08	Xenon Pharmaceuticals Insider Sold Shares Worth $330,290, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Adjusts Price Target on Xenon Pharmaceuticals to $62 From $50, Maintains Buy Rating	Mar. 01	MT
RBC Trims Price Target on Xenon Pharmaceuticals to $55 From $56, Keeps Outperform, Speculative Risk	Mar. 01	MT
Wedbush Raises Xenon Pharmaceuticals' PT to $51 From $46, Continues to See XEN1101 as Differentiated Asset; Maintains Outperform Rating	Mar. 01	MT
Citigroup Initiates Xenon Pharmaceuticals With Buy Rating, Price Target is $62	Jan. 04	MT
Stifel Adjusts Price Target on Xenon Pharmaceuticals to $62 From $53, Maintains Buy Rating	Dec. 18	MT
Baird Initiates Xenon Pharmaceuticals With Outperform Rating, Price Target is $63	Dec. 08	MT
RBC Adjusts Xenon Pharmaceuticals' Price Target to $56 From $51, Maintains Outperform Rating	Nov. 28	MT
Wedbush Trims Xenon Pharmaceuticals' PT to $46 From $47, Says X-TOLE2 Enrollment Will Complete in H2 2024; Maintains Outperform Rating	Nov. 09	MT
Wedbush Raises Xenon Pharmaceuticals' Price Target to $47 From $44, Keeps Outperform Rating	23-05-10	MT
Cantor Fitzgerald Starts Xenon Pharmaceuticals at Overweight With $58 Price Target	23-04-25	MT
JPMorgan Adjusts Xenon Pharmaceuticals Price Target to $55 From $54, Maintains Overweight Rating	23-04-25	MT
Needham Adjusts Xenon Pharmaceuticals' Price Target to $50 From $48, Maintains Buy Rating	23-03-02	MT
Wedbush Lowers Xenon Pharmaceuticals' PT to $44 From $46, Shifts XEN1101 Launch Timing, Makes Near-Term Spending Adjustments; Keeps Outperform Rating	23-03-02	MT
RBC Lifts Price Target on Xenon Pharmaceuticals to $51 From $49 Amid Increased Confidence on Patents, Keeps Outperform Rating, Speculative Risk Qualifier	23-01-31	MT
Goldman Sachs Initiates Coverage on Xenon Pharmaceuticals With Buy Rating, $60 Price Target	22-12-14	MT
Cowen Starts Xenon Pharmaceuticals at Outperform	22-12-12	MT
Wells Fargo Initiates Xenon Pharmaceuticals With Overweight Rating, Price Target is $50	22-11-28	MT
Guggenheim Adjusts Price Target on Xenon Pharmaceuticals to $49 From $53, Maintains Buy Rating	22-11-11	MT
Wedbush Lowers Xenon Pharmaceuticals' Price Target to $46 From $50, Keeps Outperform Rating	22-11-09	MT
Raymond James Starts Xenon Pharmaceuticals at Outperform With $52 Price Target	22-10-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Analyst Reco.

Filters